home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Evolving Regulatory expectation for Particulates in Biologics

 
  March 24, 2010  
     
 


Complianceonline, Online Web Event
2010-04-29


This webinar addresses evolving regulatory requirements for particulates and the techniques suitable for testing and characterizing sub-visible particulates in therapeutic formulations.

Why Should You Attend:

Particulate analysis in Protein Therapeutics has received increasing regulatory attention due to the correlation of aggregates and particles in protein therapeutics with immunogenicity. Recent FDA-Industry meetings have focused on the need for analysis of particulates smaller than the size range measured by the USP Light Obscuration test and the instrumentation available to perform such testing.

This webinar will discuss the current regulatory requirements for testing protein therapeutics for particulates, followed by a discussion of various available methods including the simplest QC friendly techniques such as SDS-PAGE to characterization methods such as Analytical Ultracentrifugation, Field Flow Fractionation and Laser Diffraction. The instrumentation available, the advantages and disadvantages of these methods will be discussed.

Areas Covered in the Seminar:

  • Current Regulatory requirements for testing particulates in protein Therapeutics.
  • The limitations of the USP methods for testing Particulates.
  • What are the methods available for analysis of subvisible particles in protein therapeutics?
  • Comparison of size ranges, sensitivity limits and capabilities of the various methods.
  • Equipment available for performing these tests.
  • Advantages and disadvantages of the methods.
 
 
Organized by: ComplianceOnline
Invited Speakers: Nanda Subbarao, Dr. Subbarao received her Ph.D. in Bio-organic Chemistry from the Indian Institute of Technology, Bombay, India. Her hands-on industrial experience covers stability and laboratory cGMP systems for both biologics and conventional drugs. She has extensive experience in evaluation of analytical methods and method validation for products ranging from conventional drugs, well characterized proteins, vaccines, cell therapy and gene therapy products, ranging from pre-clinical phase to commercial phases.
 
Deadline for Abstracts: Call contact
 
Registration:
Online Event
EVENT INFORMATION: Contact Admin, Phone: +1-650-620-3915, Fax number: +1-650-963-2556

E-mail: admin@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.